4 result(s) displayed (1 - 4 of 4):

Glaxo, Novartis, Roche, Lilly back same company (from Corporate Dealmaker)

In an interesting play, four rival drug giants are using their venture capital arms to back a company they think has come up with a major new class of therapeutics. Biotech company Aileron Therapeutics received financing from GlaxoSmithKline plc (NYSE:GSK), Novartis AG (NYSE:NVS), Roche Holding AG (SWX:ROG) and Eli Lilly...

Posted on June 8, 2009 3:30 PM

More musings on pharma megamergers (from Corporate Dealmaker)

Pfizer Inc.'s (NYSE:PFE) $68 billion acquisition of Wyeth (NYSE:WYE) and Merck & Co.'s (NYSE:MRK) $41 billion bid for Schering Plough Corp. (NYSE:SGP) sparked fresh speculation on whether pharma megamergers create value and whether industry consolidation would continue. We've done our share of analysis. Recently, Baz Hiralal posted this solid roundup...

Posted on June 2, 2009 2:46 PM

Roche and Genentech's first post-merger setback (from Corporate Dealmaker)

Now a wholly owned division of Roche Holding AG (SWX:ROG), Genentech Inc. (NYSE:DNA) said late Wednesday, April 8, it would withdraw its psoriasis drug Raptiva from the U.S. market because of the threat of a deadly brain infection.The news is the first post-merger setback for Roche, which consummated late...

Posted on April 8, 2009 5:20 PM

Big Pharma bulks up on biotech acquisitions (from Corporate Dealmaker)

Big Pharma companies have been racing to acquire smaller biotech companies to bulk up on technology as they face patent losses on top-selling drugs. Here are some of the latest deals: Sanofi-Aventis SA agreed to buy British vaccine maker Acambis plc for £276 million ($547.8 million) in order to secure...

Posted on July 25, 2008 4:49 PM